Poor
Not Aligned
Patient Risk:
Medium
Summary
Only a minority of the provided claims can be assessed using the supplied atorvastatin (LIPITOR) label excerpts; multiple furosemide-specific and Lipitor–furosemide interaction claims are not supported by the provided label text and several related mechanistic statements are unsupported or speculative.
Category Scores
Accurate Statements
Lipitor belongs to the HMG-CoA reductase inhibitor class of drugs.
12.1 Mechanism of Action: “LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase…”
Taking Lipitor can be associated with a risk of skeletal muscle effects such as myopathy (muscle aches or muscle weakness).
5.1 Skeletal Muscle: “Atorvastatin… occasionally causes myopathy, defined as muscle aches or muscle weakness…”
Muscle pain or weakness should be reported promptly to a healthcare provider.
5.1 Skeletal Muscle: “Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness…”; 17.1 Muscle Pain: “told to report promptly any unexplained muscle pain, tenderness, or weakness.”
Unsupported Statements
Furosemide is a loop diuretic that increases urine production to help the body get rid of excess fluid.
No furosemide information is present in the supplied label excerpts.
Furosemide is used to treat edema (swelling).
No furosemide indications are present in the supplied label excerpts.
Furosemide is used to treat high blood pressure.
No furosemide indications are present in the supplied label excerpts.
Furosemide is used to treat congestive heart failure.
No furosemide indications are present in the supplied label excerpts.
Taking Lipitor and furosemide together can increase the risk of muscle damage.
The supplied LIPITOR label excerpt lists specific interacting agents for increased myopathy/rhabdomyolysis risk, but furosemide is not mentioned; no statement supports this specific drug-pair interaction.
Muscle damage from Lipitor and furosemide can lead to muscle pain, weakness, and fatigue.
Muscle pain/weakness reporting is supported for atorvastatin myopathy, but the linkage to furosemide is not supported; fatigue is mentioned as a postmarketing adverse reaction, but not in connection with this specific combination.
Taking Lipitor and furosemide together can increase the risk of kidney damage.
The label excerpt discusses renal failure secondary to rhabdomyolysis risk in context of statin class events, but does not support an interaction-specific claim involving furosemide.
Furosemide can increase the risk of kidney damage particularly in individuals with pre-existing kidney disease.
No furosemide renal-risk information is present in the supplied label excerpts.
Furosemide can cause electrolyte imbalance, particularly potassium levels.
No furosemide electrolyte information is present in the supplied label excerpts.
The electrolyte imbalance caused by furosemide can be exacerbated by Lipitor.
No electrolyte/ potassium interaction between atorvastatin and furosemide is present in the supplied label excerpts.
Taking Lipitor and furosemide together can increase the risk of bleeding.
No bleeding risk or Lipitor–furosemide interaction is present in the supplied label excerpts.
The increased risk of bleeding with Lipitor and furosemide is particularly in individuals with a history of bleeding disorders.
No bleeding risk or relevant risk-stratification is present in the supplied label excerpts.
Furosemide can increase the levels of certain enzymes in the liver.
No furosemide hepatic-enzyme information is present in the supplied label excerpts.
Increased liver enzyme levels from furosemide can lead to increased metabolism of Lipitor.
No furosemide hepatic-enzyme claim is supported; additionally, no such pharmacokinetic/metabolism relationship is provided in the supplied atorvastatin label excerpts.
Increased metabolism of Lipitor can result in reduced levels of Lipitor in the blood.
No statement in the supplied label excerpts supports this mechanism or relationship, especially in context of furosemide.
Reduced Lipitor levels in the blood can lead to reduced efficacy.
No efficacy relationship to reduced atorvastatin levels is stated in the supplied excerpts.
Monitoring kidney function is recommended to ensure furosemide is not causing kidney damage.
The supplied label excerpt does not provide a recommendation about monitoring kidney function for furosemide; it only notes closer monitoring in patients with a history of renal impairment for skeletal muscle effects (statin-related).
Monitoring electrolyte levels, particularly potassium, is recommended to ensure furosemide is not causing an imbalance.
No electrolyte/potassium monitoring recommendation or furosemide-specific monitoring is present in the supplied label excerpts.
Contradictions
Important Omissions
Drug-interaction monitoring and risk reduction details in the provided label are specific to atorvastatin interacting agents (e.g., cyclosporine, certain macrolides/azole antifungals/ HIV protease inhibitors, fibric acid derivatives, niacin) rather than furosemide.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims assert increased risks (muscle damage, kidney damage, bleeding, electrolyte imbalance, hepatic enzyme changes) from a Lipitor–furosemide combination, but none are supported by the supplied atorvastatin label excerpts; unsupported interaction claims could mislead safety monitoring expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple furosemide- and Lipitor–furosemide-specific interaction and safety-monitoring claims are not supported by the provided FDA label excerpts (which discuss atorvastatin mechanisms, skeletal muscle and liver dysfunction warnings, and drug interactions with other specified agents).
Suggested Improvement
Limit interaction/safety claims to those explicitly listed in the provided LIPITOR label excerpts (e.g., increased myopathy/rhabdomyolysis risk with cyclosporine, fibric acid derivatives, niacin, and strong CYP3A4 inhibitors) and avoid attributing effects to furosemide or asserting bleeding/electrolyte/hepatic-enzyme/monitoring recommendations that are absent from the supplied label text.